{"url_path":"/sec/ikt/10-q/2026/item-5","section_key":"item-5","section_title":"Item 5 Other Information.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-12","source_url":"https://www.sec.gov/Archives/edgar/data/1750149/0001193125-26-219641-index.html","accession_number":"0001193125-26-219641","cik":"0001750149","ticker":"IKT","issuer_name":"Inhibikase Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1750149/0001193125-26-219641-index.html","primary_entity_key":"0001750149","primary_entity_name":"Inhibikase Therapeutics, Inc."},"word_count":64,"has_tables":true,"body_markdown":"Item 5. Other Information.\n\n(c) Rule 10b5-1 Trading Plans\n\nNone of our directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) adopted or terminated a Rule 10b5-1 trading plan or arrangement or a non-Rule 10b5-1 trading plan or arrangement, as defined in Item 408(c) of Regulation S-K, during the fiscal quarter ended March 31, 2026 covered by this Quarterly Report.\n\n \n\n \n\n \n\n29"}